Discovery of potent and selective reversible Bruton's tyrosine kinase inhibitors.
Qiu, H., Ali, Z., Bender, A., Caldwell, R., Chen, Y.Y., Fang, Z., Gardberg, A., Glaser, N., Goettsche, A., Goutopoulos, A., Grenningloh, R., Hanschke, B., Head, J., Johnson, T., Jones, C., Jones, R., Kulkarni, S., Maurer, C., Morandi, F., Neagu, C., Poetzsch, S., Potnick, J., Schmidt, R., Roe, K., Viacava Follis, A., Wing, C., Zhu, X., Sherer, B.(2021) Bioorg Med Chem 40: 116163-116163
- PubMed: 33932711 
- DOI: 10.1016/j.bmc.2021.116163
- Primary Citation of Related Structures:  
7KXL, 7KXM, 7KXN, 7KXO, 7KXP, 7KXQ - PubMed Abstract: 
Bruton's tyrosine kinase (BTK) is a cytoplasmic, non-receptor tyrosine kinase member of the TEC family of tyrosine kinases. Pre-clinical and clinical data have shown that targeting BTK can be used for the treatment for B-cell disorders. Here we disclose the discovery of a novel imidazo[4,5-b]pyridine series of potent, selective reversible BTK inhibitors through a rational design approach ...